IOVA Stock Forecast 2025-2026
Distance to IOVA Price Targets
IOVA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Iovance (IOVA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on IOVA and similar high-potential opportunities.
Latest IOVA Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, IOVA has a bullish consensus with a median price target of $18.00 (ranging from $5.00 to $32.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $3.36, the median forecast implies a 435.7% upside. This outlook is supported by 11 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 852.4% upside. Conversely, the most conservative target is provided by Peter Lawson at Barclays, suggesting a 48.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IOVA Analyst Ratings
IOVA Price Target Range
Latest IOVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IOVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2025 | Goldman Sachs | Andrea Tan | Buy | Maintains | $16.00 |
| Apr 14, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $5.00 |
| Mar 3, 2025 | Goldman Sachs | Andrea Tan | Buy | Maintains | $19.00 |
| Mar 3, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $30.00 |
| Mar 3, 2025 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $15.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $32.00 |
| Feb 28, 2025 | Piper Sandler | Joseph Catanzaro | Neutral | Maintains | $6.00 |
| Feb 28, 2025 | Baird | Michael Ulz | Outperform | Maintains | $20.00 |
| Jan 31, 2025 | Piper Sandler | Joseph Catanzaro | Neutral | Maintains | $7.50 |
| Nov 6, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $32.00 |
| Oct 24, 2024 | UBS | David Dai | Buy | Initiates | $17.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $32.00 |
| Jul 29, 2024 | Piper Sandler | Joseph Catanzaro | Neutral | Downgrade | $10.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $32.00 |
| Jun 20, 2024 | JMP Securities | Reni Benjamin | Market Outperform | Maintains | $23.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $32.00 |
| May 31, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $32.00 |
| May 24, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $32.00 |
| May 10, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $32.00 |
| Mar 14, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $19.00 |
Iovance Biotherapeutics, Inc. (IOVA) Competitors
The following stocks are similar to Iovance based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Iovance Biotherapeutics, Inc. (IOVA) Financial Data
Iovance Biotherapeutics, Inc. has a market capitalization of $1.05B with a P/E ratio of -2.6x. The company generates $164.07M in trailing twelve-month revenue with a -226.8% profit margin.
Revenue growth is +15,189.2% quarter-over-quarter, while maintaining an operating margin of -117.5% and return on equity of -57.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Iovance Biotherapeutics, Inc. (IOVA) Business Model
About Iovance Biotherapeutics, Inc.
Develops innovative cancer immunotherapy treatments.
Iovance Biotherapeutics makes money by developing and commercializing its Tumor-Infiltrating Lymphocyte (TIL) therapy, which utilizes a patient's immune cells to fight cancer. The company targets advanced melanoma, cervical cancer, and other solid tumors, generating revenue through successful clinical trials and eventual therapy sales.
As a significant player in the biotechnology sector, Iovance is positioned well amidst the growing demand for personalized medicine. The company is headquartered in San Carlos, California, and is focused on transforming healthcare through scientific innovation in immuno-oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
838
CEO
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Country
United States
IPO Year
2017
Website
www.iovance.comIovance Biotherapeutics, Inc. (IOVA) Latest News & Analysis
Latest News
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.
1 day agoIovance Biotherapeutics (IOVA) received regulatory approval for its cellular therapy Amtagvi, aimed at treating unresectable or metastatic melanoma, indicating potential growth for investors.
Iovance's approval of Amtagvi positions it for growth in the oncology market, potentially increasing revenue and attracting investor interest due to its promising therapeutic applications.
Iovance Biotherapeutics will present pre-clinical data for IOV-5001 and five-year outcomes from the C-144-01 study at upcoming AACR and ASCO Annual Meetings, respectively.
Iovance's announcements on pre-clinical data and long-term outcomes for TIL therapies could boost investor confidence, indicating potential advancements in cancer treatment and future revenue growth.
Investors may find it challenging to select stocks for short-term gains while managing performance expectations, as distinguishing between varying investment prospects is key.
Short-term stock picking can be risky and uncertain. Investors need to carefully assess performance expectations to avoid potential losses and enhance decision-making.
Iovance Biotherapeutics granted inducement stock options for 297,600 shares to fifty new non-executive employees on April 17, 2025.
The grant of stock options to new employees may indicate Iovance's growth and confidence in future performance, potentially affecting stock value and investor sentiment.
Is Iovance Biotherapeutics a Millionaire-Maker?
10 days agoSome investors liken biotech stocks to lottery tickets, suggesting that investing in biotech often results in financial losses similar to purchasing lottery tickets.
The comparison suggests that biotech stocks may carry high risks with low returns, prompting investors to reassess their strategies and potential losses in this sector.
Biotech companies may offer significant returns within a year due to clinical or regulatory advancements, with Wall Street projecting share increases for several firms in the next 12 months.
Strong clinical or regulatory advancements in biotech can lead to rapid share price increases, presenting lucrative opportunities for investors in the sector over the next year.
Frequently Asked Questions About IOVA Stock
What is Iovance Biotherapeutics, Inc.'s (IOVA) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Iovance Biotherapeutics, Inc. (IOVA) has a median price target of $18.00. The highest price target is $32.00 and the lowest is $5.00.
Is IOVA stock a good investment in 2025?
According to current analyst ratings, IOVA has 11 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IOVA stock?
Wall Street analysts predict IOVA stock could reach $18.00 in the next 12 months. This represents a 435.7% increase from the current price of $3.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Iovance Biotherapeutics, Inc.'s business model?
Iovance Biotherapeutics makes money by developing and commercializing its Tumor-Infiltrating Lymphocyte (TIL) therapy, which utilizes a patient's immune cells to fight cancer. The company targets advanced melanoma, cervical cancer, and other solid tumors, generating revenue through successful clinical trials and eventual therapy sales.
What is the highest forecasted price for IOVA Iovance Biotherapeutics, Inc.?
The highest price target for IOVA is $32.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 852.4% increase from the current price of $3.36.
What is the lowest forecasted price for IOVA Iovance Biotherapeutics, Inc.?
The lowest price target for IOVA is $5.00 from Peter Lawson at Barclays, which represents a 48.8% increase from the current price of $3.36.
What is the overall IOVA consensus from analysts for Iovance Biotherapeutics, Inc.?
The overall analyst consensus for IOVA is bullish. Out of 19 Wall Street analysts, 11 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $18.00.
How accurate are IOVA stock price projections?
Stock price projections, including those for Iovance Biotherapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.